{"name":"Cognition Therapeutics","slug":"cognition-therapeutics","ticker":"","exchange":"","domain":"cognition.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":37187000,"netIncome":-23487000,"cash":36810000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"zervimesine","genericName":"zervimesine","slug":"zervimesine","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"zervimesine","genericName":"zervimesine","slug":"zervimesine","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOdW1VdjVidGxkb2FYdE91eFZGYkd3NXJ0TXpVUXNGYjVacHRLVXloNkhOT3l6OF94dUdzVUpJV08zdXFwTVQwN1otalUwRlJYWHlFVzNsYllJem5LazNQQVlLQm41SUtqZ3dSMDNfQzB2S3JxUFkyMXpmQk9NdVNFRnR5ckhRbW9hOThtei1nMGVCNHprdmltcmtiZmctT3B1NkFlRm41eHc5OVJLMkFzbkJWYS1nVlhIR25LMlhPeGpqYUNYQ3lz?oc=5","date":"2026-03-31","type":"pipeline","source":"GlobeNewswire","summary":"Cognition Therapeutics CEO Issues Letter to Shareholders - GlobeNewswire","headline":"Cognition Therapeutics CEO Issues Letter to Shareholders","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-28","type":"pipeline","source":"simplywall.st","summary":"Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation - simplywall.st","headline":"Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQS1laNjRidE9PWlpOYW94SHVjUzVWVXpqMXFsREwtUzM4Z2M4Zk1DeEtaN3dSTUJmTVRvM1FpcURTUjNWM1pLN2lQODBEMjdUd3JKU0VidlVnMklCV2JXcXJoQXdibTRoLTRwNU9tNkxsSXltZ3d5OThFbzNLMG1OeFpwQXV1djhnNkJtUTk4VERvTlMxZWQ2RmJn?oc=5","date":"2026-03-26","type":"earnings","source":"Benzinga","summary":"Earnings Scheduled For March 26, 2026 - Benzinga","headline":"Earnings Scheduled For March 26, 2026","sentiment":"neutral"},{"date":"2026-03-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxQU25QclBtQ3Bic3Q2M21XejVvNG5XWV8yeHJFUjBFb2dIUzhWbVp1cFdOTnYycW9PTWtzZU1DZ281S19pcmZBeGFUYkJtQXFmSWoxXzdLZmdpLVlmQkloOFhsRlpDY0hvY19vcmd0cUQwckZXQkpLZ25VRGJiTlBJVEM2d095SkJlMHVyNDg5QkRzOVhiVXo0NkJYcEgtSzBWU3FEMlAyc0lFRGxMNU8wUXpmeFVnRHJOQl9uVDNPblBvV1p5RkZrYzVZdUFCVldGRHY1VUFPYmhXY1U3em1EVkw5cTcyd21UTGZub2s3cVRkNlRVbk1jSXI0VC01NjUyU1BIcUVzcVRMRl9fSlo5LXNWY216TFlLM0FVR1NLanJxc1N2QnhjWUZKN3pUUFlYVlE?oc=5","date":"2026-03-17","type":"pipeline","source":"GlobeNewswire","summary":"Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 - GlobeNewswire","headline":"Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodi","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNUTlBMXJCN0MzODBoT2JGaWdKaVZHSEh0NEY5RS0tXzY1MmlBeGszc2k1UkFDV25LRTlQNW56aVFMeWdMcGNkMGlIYTZXQlFGWURvYjhaRUYtUktSbkNJUy1BSGI5SjZVMkZHeEJmOFRqOThxazJFaUtMUldGWUM4TVdleDV3QnBjTWk3SGI5OU5qaWVRVUE?oc=5","date":"2026-02-12","type":"pipeline","source":"PharmTech.com","summary":"European Biotechs Impacting Treatment of Alzheimer’s Disease - PharmTech.com","headline":"European Biotechs Impacting Treatment of Alzheimer’s Disease","sentiment":"neutral"},{"date":"2026-01-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOcFhTMEc0NXVXdm0wYmdDdUo5dmVzMVI3S1dBei1CWm9xTExzRGhVaXQ3XzdET2tpWWZmeHhMdU5oMTVoWFFMTEQ0V1RmVDdWTnNHQkw5cjNoRWZPQU9STFl3LXo1SjhHS3FPaWtuMnNMQWZvdGZ0SlhGalVva1lDQlItaTNlM2lhTVlZbXY5ZnlIeFgxYU9vRk9mbWpFanZWREE?oc=5","date":"2025-12-03","type":"trial","source":"The Clinical Trial Vanguard","summary":"Cognition Therapeutics Plans Phase 3 for Alzheimer’s Drug - The Clinical Trial Vanguard","headline":"Cognition Therapeutics Plans Phase 3 for Alzheimer’s Drug","sentiment":"neutral"},{"date":"2025-11-06","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNVHdLOUpTX2x1a2FoeVVnU1BQTWVlcS1wZWd3ZXM4a1hNclNremVCMi1uY1lhckhkbmNIdXQwbzhzVzE0aC1QME1HNWFYVWxoUlh6c3VaQlpPSG5QOFRyc3h3Y04tYlZuazhtdnZmU0sxR2dlN1F5SHhLZnpNZjdQZFlvN0c2dzlFWW5EVFcxUm94NXFua0pVakUySDFLdmVqaDFlajYxWm1RUQ?oc=5","date":"2025-08-20","type":"pipeline","source":"BioSpace","summary":"5 Biotechs Taking the Pipeline-in-a-Product Approach to Drug Development - BioSpace","headline":"5 Biotechs Taking the Pipeline-in-a-Product Approach to Drug Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOSnhVT3VaNHJJQlRfVHJsc0lBV3J4S1MxdEgxVU55eXI5bktJQjlvdGRZSWJuaTNGVHRlcGEyLVVFZ2hRcjBKYTRVNEF3c3RvdlFIZlBGTHBEYllrUjg5TWFkdTJhM1Y1OXAzUkZJQUppYjhiWWN2TGFRN0NrSElDRUdQcU9OMFZleFJ6OXlKNkRpb1dXTno5ZGNyMkdHRlh4cUFQUGZPVnIxTmNtOGc?oc=5","date":"2025-07-30","type":"trial","source":"Clinical Trials Arena","summary":"Cognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s - Clinical Trials Arena","headline":"Cognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":37187000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-23487000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":36810000,"cashHistory":[],"totalAssets":48390000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}